World Pharma News Digest - 28.04.2014
7 views
Skip to first unread message
Ruslan David
Apr 27, 2014, 6:39:01 PM4/27/14
to worldph...@googlegroups.com
Novartis delivered solid sales and profit growth in the first quarter of 2014
Subsequent to the quarter end, Novartis announced that it had reached definitive agreements with GlaxoSmithKline plc (GSK) and Eli Lilly and Company (Lilly) on a set of transactions. In an inter-conditional transaction with GSK: (1) Novartis agreed to acquire GSK oncology products and to become GSK's preferred commercialization partner for its oncology pipeline for a USD 14.5 billion payment and up to USD 1.5 billion contingent on a development milestone;
Read more...
http://www.worldpharmanews.com/novartis/2761-novartis-delivered-solid-sales-and-profit-growth-in-the-first-quarter-of-2014
Bristol-Myers Squibb ranks first on 2014 Best Corporate Citizens List
Bristol-Myers Squibb Company (NYSE:BMY) has been ranked No. 1 on Corporate Responsibility magazine's 2014 list of the 100 Best Corporate Citizens, a leading benchmark for socially responsible investors and other stakeholders. Bristol-Myers Squibb is the only company to achieve the No. 1 ranking three times, including 2009 and 2012, and has ranked among the top 10 each of the last six years.
Read more...
http://www.worldpharmanews.com/bms/2760-bristol-myers-squibb-ranks-first-on-2014-best-corporate-citizens-list
Aspirin can reduce colorectal cancer risks for those with specific gene
The humble aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce the risk of heart attacks: lowering colon cancer risk among people with high levels of a specific type of gene. The extraordinary finding comes from a multi-institutional team that analyzed data and other material from two long-term studies involving nearly 128,000 participants.
Read more...
http://www.worldpharmanews.com/research/2759-aspirin-can-reduce-colorectal-cancer-risks-for-those-with-specific-gene
Novartis announces portfolio transformation
Novartis has reached a definitive agreement with GlaxoSmithKline plc (GSK) to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. Under the agreement, Novartis would strengthen the company's innovative pharmaceuticals business by acquiring GSK oncology products, and would divest Vaccines (excluding flu) to them.
Read more...
http://www.worldpharmanews.com/novartis/2758-novartis-announces-portfolio-transformation
Chaperone compounds offer new approach to Alzheimer's treatment
A team of researchers from Columbia University Medical Center (CUMC), Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer's disease involving the so-called retromer protein complex. Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating the potentially toxic byproduct amyloid-beta, which is thought to contribute to the development of Alzheimer's.
Read more...
http://www.worldpharmanews.com/research/2757-chaperone-compounds-offer-new-approach-to-alzheimers-treatment
Abbott reports first-quarter 2014 results
Abbott (NYSE: ABT) has announced financial results for the first quarter ended March 31, 2014. First-quarter 2014 worldwide sales of $5.2 billion increased 0.5 percent on an operational basis and decreased 2.5 percent on a reported basis, including an unfavorable 3.0 percent effect of foreign exchange.
Read more...
http://www.worldpharmanews.com/abbott/2756-abbott-reports-first-quarter-2014-results
Roche with good start in 2014
Group sales rose 5% in the first quarter, driven by demand for cancer medicines (in particular the HER2 breast cancer franchise, Avastin and MabThera/Rituxan), as well as Actemra/RoActemra for rheumatoid arthritis. Sales of Xeloda, a chemotherapy drug, were lower as the product is now off patent and faces generic competition in the United States and Europe.
Read more...
http://www.worldpharmanews.com/roche/2755-roche-with-good-start-in-2014
PharmaNews.eu / Latest News
SMARTT e-Patch is a winner at the French 'Worldwide Innovation Challenge'
http://www.pharmanews.eu/research-and-development/1436-smartt-e-patch-is-a-winner-at-the-french-worldwide-innovation-challenge
'Dustman' protein helps bin cancer cells
http://www.pharmanews.eu/research-and-development/1435-dustman-protein-helps-bin-cancer-cells
Positive trial data suggests Exenatide has the potential to be a disease modifying agent in Parkinson's disease
http://www.pharmanews.eu/research-and-development/1434-positive-trial-data-suggests-exenatide-has-the-potential-to-be-a-disease-modifying-agent-in-parkinsons-disease
Novartis announces that the XOVA (eXcellence in Ophthalmology Vision Award) is now open for entries
http://www.pharmanews.eu/novartis/1433-novartis-announces-that-the-xova-excellence-in-ophthalmology-vision-award-is-now-open-for-entries
Unexpected results in cancer drug trial
http://www.pharmanews.eu/research-and-development/1432-unexpected-results-in-cancer-drug-trial
Novel plant biotechnology approach for sustainable production of pharmaceutical compounds
http://www.pharmanews.eu/research-and-development/1431-novel-plant-biotechnology-approach-for-sustainable-production-of-pharmaceutical-compounds
Choices in TB vaccine development
http://www.pharmanews.eu/research-and-development/1430-choices-in-tb-vaccine-development
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Subsequent to the quarter end, Novartis announced that it had reached definitive agreements with GlaxoSmithKline plc (GSK) and Eli Lilly and Company (Lilly) on a set of transactions. In an inter-conditional transaction with GSK: (1) Novartis agreed to acquire GSK oncology products and to become GSK's preferred commercialization partner for its oncology pipeline for a USD 14.5 billion payment and up to USD 1.5 billion contingent on a development milestone;
Read more...
http://www.worldpharmanews.com/novartis/2761-novartis-delivered-solid-sales-and-profit-growth-in-the-first-quarter-of-2014
Bristol-Myers Squibb ranks first on 2014 Best Corporate Citizens List
Bristol-Myers Squibb Company (NYSE:BMY) has been ranked No. 1 on Corporate Responsibility magazine's 2014 list of the 100 Best Corporate Citizens, a leading benchmark for socially responsible investors and other stakeholders. Bristol-Myers Squibb is the only company to achieve the No. 1 ranking three times, including 2009 and 2012, and has ranked among the top 10 each of the last six years.
Read more...
http://www.worldpharmanews.com/bms/2760-bristol-myers-squibb-ranks-first-on-2014-best-corporate-citizens-list
Aspirin can reduce colorectal cancer risks for those with specific gene
The humble aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce the risk of heart attacks: lowering colon cancer risk among people with high levels of a specific type of gene. The extraordinary finding comes from a multi-institutional team that analyzed data and other material from two long-term studies involving nearly 128,000 participants.
Read more...
http://www.worldpharmanews.com/research/2759-aspirin-can-reduce-colorectal-cancer-risks-for-those-with-specific-gene
Novartis announces portfolio transformation
Novartis has reached a definitive agreement with GlaxoSmithKline plc (GSK) to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. Under the agreement, Novartis would strengthen the company's innovative pharmaceuticals business by acquiring GSK oncology products, and would divest Vaccines (excluding flu) to them.
Read more...
http://www.worldpharmanews.com/novartis/2758-novartis-announces-portfolio-transformation
Chaperone compounds offer new approach to Alzheimer's treatment
A team of researchers from Columbia University Medical Center (CUMC), Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer's disease involving the so-called retromer protein complex. Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating the potentially toxic byproduct amyloid-beta, which is thought to contribute to the development of Alzheimer's.
Read more...
http://www.worldpharmanews.com/research/2757-chaperone-compounds-offer-new-approach-to-alzheimers-treatment
Abbott reports first-quarter 2014 results
Abbott (NYSE: ABT) has announced financial results for the first quarter ended March 31, 2014. First-quarter 2014 worldwide sales of $5.2 billion increased 0.5 percent on an operational basis and decreased 2.5 percent on a reported basis, including an unfavorable 3.0 percent effect of foreign exchange.
Read more...
http://www.worldpharmanews.com/abbott/2756-abbott-reports-first-quarter-2014-results
Roche with good start in 2014
Group sales rose 5% in the first quarter, driven by demand for cancer medicines (in particular the HER2 breast cancer franchise, Avastin and MabThera/Rituxan), as well as Actemra/RoActemra for rheumatoid arthritis. Sales of Xeloda, a chemotherapy drug, were lower as the product is now off patent and faces generic competition in the United States and Europe.
Read more...
http://www.worldpharmanews.com/roche/2755-roche-with-good-start-in-2014
PharmaNews.eu / Latest News
SMARTT e-Patch is a winner at the French 'Worldwide Innovation Challenge'
http://www.pharmanews.eu/research-and-development/1436-smartt-e-patch-is-a-winner-at-the-french-worldwide-innovation-challenge
'Dustman' protein helps bin cancer cells
http://www.pharmanews.eu/research-and-development/1435-dustman-protein-helps-bin-cancer-cells
Positive trial data suggests Exenatide has the potential to be a disease modifying agent in Parkinson's disease
http://www.pharmanews.eu/research-and-development/1434-positive-trial-data-suggests-exenatide-has-the-potential-to-be-a-disease-modifying-agent-in-parkinsons-disease
Novartis announces that the XOVA (eXcellence in Ophthalmology Vision Award) is now open for entries
http://www.pharmanews.eu/novartis/1433-novartis-announces-that-the-xova-excellence-in-ophthalmology-vision-award-is-now-open-for-entries
Unexpected results in cancer drug trial
http://www.pharmanews.eu/research-and-development/1432-unexpected-results-in-cancer-drug-trial
Novel plant biotechnology approach for sustainable production of pharmaceutical compounds
http://www.pharmanews.eu/research-and-development/1431-novel-plant-biotechnology-approach-for-sustainable-production-of-pharmaceutical-compounds
Choices in TB vaccine development
http://www.pharmanews.eu/research-and-development/1430-choices-in-tb-vaccine-development
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages